TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12439364
Drug: Fenoldopam (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (a selective dopamine receptor agonist) used as an adjunct during PCI for prevention of radiocontrast nephropathy (RCN)
Study: 8007592
Drug: Cyclosporine therapy
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine therapy with physiological infusion of vasopressin
Study: 373073
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg trimipramine
Study: 31099085
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D3 + 2000 mg calcium/d (n = 73)
Study: 25637380
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (arm A): FEC100 (500, 100, and 500 mg/m(2) for 3 cycles) followed by docetaxel (100 mg/m(2) for 3 cycles)
Study: 25637380
Drug: Adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted treatment (arm B): 2 cycles of FEC100, switch to docetaxel if tumor size decreased by <30% after 2 cycles or <50% after 4 cycles; otherwise, FEC100 for six cycles before surgery
Study: 21392667
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion (RME) followed by transpalatal arch (TPA) therapy and extraction of deciduous canines
Study: 25549517
Drug: No orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No orthodontic treatment (control group)
Study: 19443338
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy with docetaxel plus gemcitabine and concomitant treatment with docetaxel plus carboplatin plus 60 Gy TRT
Study: 19443338
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel plus gemcitabine and concomitant treatment with docetaxel plus carboplatin plus 60 Gy TRT
Study: 19443338
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of RT treatment
Study: 19443338
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of induction or consolidation plus concomitant treatment
Study: 18633754
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg/day for three months
Study: 12815786
Drug: MAG i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG i.v. group (25 patients) received daily doses of 2.5 ml of 20% MgSO4 per each 500 ml of transfused fluids for 5 days (day of surgery + 4 days post-surgery)
Study: 11150431
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (200 mg/m² per cycle) with etoposide and bleomycin
Study: 11150431
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cisplatin (100 mg/m² per cycle) with etoposide and bleomycin
Study: 31243790
Drug: DS-1040 single
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1040 single ascending doses (50, 100, 200, or 400 mg)
Study: 31243790
Drug: DS-1040 multiple
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1040 multiple ascending doses (100 mg once daily, 200 mg once daily, or 150 mg twice daily)
Study: 31243790
Drug: DS-1040 single
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1040 single and multiple doses
Study: 22358132
Drug: LAM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM plus adefovir (ADV) therapy
Study: 20585300
Drug: Concurrent Endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Endurance and Resistance Training (CT)
Study: 12001038
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg; n=22)
Study: 10449693
Drug: Active hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active hormone preparations
Study: 7794146
Drug: Seminar on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seminar on rational prescribing of antibiotics
Study: 29263353
Drug: 5-day intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day intensive inpatient spa therapy (2 hr/day), exercise (30 min/day), and education (45 min/day)
Study: 25837016
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus oral pantoprazole therapy (n=252)
Study: 25837016
Drug: Oral pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pantoprazole alone (n=252)
Study: 19156149
Drug: Intrapericardial bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapericardial bleomycin (BLM) at 15 mg, followed by additional i.p.c. BLM 10 mg every 48 hours.
Study: 17573751
Drug: Clove oil
Normalized name: Clove Oil
DrugBank: Clove oil (DB11338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clove oil 1% cream
Study: 17573751
Drug: Control (stool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (stool softeners and lignocaine cream 5%)
Study: 15488040
Drug: 18 gauge
Normalized name: lancets 18 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 gauge (G) needle without filter
Study: 15488040
Drug: 21 gauge
Normalized name: lancets 21 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 gauge (G) needle without filter
Study: 15488040
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 18G and 21G groups of 2-mL ampoules
Study: 9407576
Drug: Psychogeriatric intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychogeriatric intervention (multidisciplinary joint treatment by a psychogeriatric team)
Study: 8485530
Drug: Usual tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual tests for carry-over effects and direct treatment effects
Study: 31142067
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 1 mg/kg intravenously for half an hour before operation and lidocaine for periprostatic nerve block (PNB)
Study: 28248620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of smoking cues and disgust content
Study: 22929086
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy for suicidal older men
Study: 21554734
Drug: Brief Strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Strategic Therapy (BST)
Study: 10229902
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, 0.05U/kg/day or a maximum of 3U/day s.c., reduced to 0.024±0.004U/kg/day due to side effects.
Study: 2055059
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ventilatory rates (8 and 16 cycles/min)
Study: 23323567
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg once daily in the morning
Study: 23323567
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg once daily in the evening
Study: 19232035
Drug: Repaglinide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (up to 6 mg/day, 2 mg three times a day)
Study: 19232035
Drug: Acarbose (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (up to 300 mg/day, 100 mg three times a day)
Study: 17402796
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg weekly or every other week
Study: 14985268
Drug: 40% l-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% l-menthol
Study: 14985268
Drug: 40% l-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% l-menthol during A fibre conduction blockade
Study: 24971433
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) tapering after antithymocyte globulin (h-ATG) for 6 months, tapered over 18 months (total of 2 years)
Study: 24971433
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) tapering after antithymocyte globulin (h-ATG)
Study: 23257009
Drug: Jinshuibao capsules
Normalized name: Jinshuibao
DrugBank: Ophiocordyceps sinensis (DB19288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinshuibao capsules (3 capsules three times a day for 2-3 courses of treatment, each course = 6 weeks)
Study: 23257009
Drug: Jinshuibao capsules
Normalized name: Jinshuibao
DrugBank: Ophiocordyceps sinensis (DB19288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinshuibao capsules
Study: 20973950
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (phone call, SMS, postal reminder)
Study: 18515690
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving therapy-primary care
Study: 16052083
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg TH9507
Study: 16052083
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg TH9507
Study: 25907003
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of solifenacin 6 mg plus TOCAS (0.4 mg)
Study: 25907003
Drug: TOCAS monotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TOCAS monotherapy (0.4 mg)
Study: 19073788
Drug: Supplemental iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental iron source (7.6 mg FeSO4 providing 0.9 mg 58Fe as FeSO4)
Study: 19073788
Drug: Nonheme food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonheme food source (orange‐fleshed sweet potato: 1.4 mg native Fe)
Study: 17093965
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (7.5 mg) 15 min before MRI
Study: 17093965
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (1 or 2 mg via nasal spray) immediately prior to MRI
Study: 11980131
Drug: Allicor 600
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allicor 600 mg/day
Study: 8147677
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg/d
Study: 8147677
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg/d + Hydrochlorothiazide 12.5 mg/d
Study: 8147677
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg/d + Hydrochlorothiazide 25 mg/d
Study: 31823152
Drug: Radium-223 (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 (55 kBq/kg) plus abiraterone acetate 1000 mg once daily and prednisone/prednisolone 5 mg twice daily
Study: 31823152
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus abiraterone acetate 1000 mg once daily and prednisone/prednisolone 5 mg twice daily
Study: 22177437
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (3200 U/d)
Study: 9328304
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 10-15 mg/kg/d
Study: 8405741
Drug: GLP-1 (7-36
Normalized name: GLP-1 (7-36) amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (7-36 amide) infusion at 1.2 pmol x kg‐1 x min‐1
Study: 3910836
Drug: Prednisone 15
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 15 mg/day
Study: 25391264
Drug: Short lymphoscintigraphy
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short lymphoscintigraphy protocol (0-2 mL of unfiltered technetium sulphur colloid injected the morning before surgery)
Study: 25391264
Drug: Long lymphoscintigraphy
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long lymphoscintigraphy protocol (0-2 mL of unfiltered technetium sulphur colloid injected the day before surgery)
Study: 14987278
Drug: Local KUVA
Normalized name: Kuvan
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Local KUVA treatment
Study: 14987278
Drug: Systemic PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic PUVA treatment
Study: 3379743
Drug: Empirical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical regimen (4.8 million U of aqueous penicillin G procaine intramuscularly and 1.0 g of probenecid orally, followed by 100 mg of oral doxycycline twice daily for seven days)
Study: 3379743
Drug: Specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific therapy for each infection as it was recognized
Study: 12671333
Drug: Various drugs
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drugs
Study: 26436473
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous acetaminophen
Study: 19230469
Drug: Capsitol‐Enabled Budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsitol‐Enabled Budesonide Inhalation Solution (CBIS) 120 microg twice daily
Study: 19230469
Drug: Pulmicort Respules
Normalized name: Pulmicort Respules
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Respules (budesonide suspension) 500 microg twice daily
Study: 17035697
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (sodium ferric gluconate complex) 250 mg i.v. weekly x 4
Study: 17035697
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulfate) 325 mg t.i.d. x 42 days
Study: 9228490
Drug: Childbirth preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Childbirth preparation with the Lamaze method
Study: 9228490
Drug: No childbirth
Approvals — FDA: no, EMA: no, PMDA: no
Description: No childbirth preparation
Study: 3331045
Drug: Imipenem/cilastatin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (0.5 g six hourly)
Study: 3331045
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ampicillin 0.5 g six hourly, metronidazole 0.5 g eight hourly, gentamicin 80 mg eight hourly)
Study: 29126824
Drug: Seventeen Days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seventeen Days (treatment intervention; sex education)
Study: 26690812
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics for the first 6 weeks of therapy
Study: 26690812
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics for the first 6 weeks of therapy
Study: 11053761
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (8 weeks)
Study: 8880820
Drug: Midazolam loading
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam loading dose 0.08 mg.kg‐1
Study: 8880820
Drug: Midazolam loading
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam loading dose 0.04 mg.kg‐1
Study: 8880820
Drug: Placebo (0.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.00 mg.kg‐1)
Study: 8299441
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg 3 times/day)
Study: 8299441
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg 3 times/day)
Study: 3522372
Drug: Weekly endoscopic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly endoscopic sclerotherapy
Study: 29526840
Drug: Average intensity/load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average intensity/load conventional physical therapy (CON) - 60% VO2max
Study: 25011274
Drug: Safflower treatment
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower treatment group
Study: 18512752
Drug: Push and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push and Release Test (P&R) in OFF medication state
Study: 18512752
Drug: Pull Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pull Test in OFF medication state
Study: 18512752
Drug: Push and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push and Release Test (P&R) in ON medication state
Study: 18512752
Drug: Pull Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pull Test in ON medication state
Study: 12844138
Drug: Theophylline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (250 mg twice daily)
Study: 1310834
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (8 mg)
Study: 1310834
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (4 mg)
Study: 2485268
Drug: Intravenous angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous angiotensin II infusions (2-16 ng min-1 kg-1)
Study: 25255799
Drug: Patient oriented
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient oriented decision aid for prioritising treatment goals in diabetes
Study: 16284203
Drug: CRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT plus medical therapy
Study: 11910263
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 mg twice daily)
Study: 11910263
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with either fluoxetine or imipramine
Study: 10622015
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections
Study: 7852498
Drug: Ovine corticotropin-releasing
Normalized name: Ovine corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine corticotropin-releasing hormone (CRH) 100 micrograms iv bolus
Study: 7852498
Drug: Human corticotropin-releasing
Normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human corticotropin-releasing hormone (CRH) 100 micrograms iv bolus
Study: 1952268
Drug: Naftidrofuryl (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (600 mg in 250 mL saline infused over six hours)
Study: 24820288
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert lotion)
Study: 22930487
Drug: Hydrocortisone 10-0-5-0
Normalized name: hydrocortisone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 10-0-5-0 mg (treatment A)
Study: 22930487
Drug: Hydrocortisone 10-5-5
Normalized name: hydrocortisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 10-5-5 mg (treatment B)
Study: 22930487
Drug: Prednisone 5
Normalized name: prednisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 5 mg (treatment C)
Study: 19180569
Drug: Soy supplements
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplements (82 mg/day aglycone equivalents)
Study: 15144425
Drug: Zonisamide (ZNS)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (ZNS) treatment
Study: 2809097
Drug: 0.10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg/kg thrice weekly
Study: 2809097
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg thrice weekly
Study: 793005
Drug: Amitriptyline tablets
Normalized name: amitriptyline Oral Tablet
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline tablets
Study: 793005
Drug: Fluphenazine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine with nortriptyline (f/n) tablets
Study: 25935863
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment (23 patients)
Study: 19740396
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive plus rotigotine (2 mg on days 1-3, 3 mg maintenance thereafter)
Study: 19740396
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patches (instead of rotigotine)
Study: 19740396
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive plus rotigotine
Study: 17578934
Drug: Daily positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily positive mood states
Study: 9672274
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg per day orally
Study: 3063718
Drug: Methylphenidate 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.15 mg/kg
Study: 3063718
Drug: Methylphenidate 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.30 mg/kg
Study: 3338232
Drug: Methylphenidate 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.50 mg/kg
Study: 20094015
Drug: 1-mg estradiol
Normalized name: estradiol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg estradiol and 0.5-mg norethisterone (hormone therapy)